Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study
IntroductionAmong white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. Meanwhile, there has also been a significant improvement in 5-year survival among patients with melanoma. This population-based cohort study investigates the five-yea...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5f72f641fe674fc49f5331b34d148773 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5f72f641fe674fc49f5331b34d148773 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5f72f641fe674fc49f5331b34d1487732021-11-16T04:50:16ZPrognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study2234-943X10.3389/fonc.2021.737399https://doaj.org/article/5f72f641fe674fc49f5331b34d1487732021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.737399/fullhttps://doaj.org/toc/2234-943XIntroductionAmong white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. Meanwhile, there has also been a significant improvement in 5-year survival among patients with melanoma. This population-based cohort study investigates the five-year melanoma-specific survival (MSS) for all melanoma cases recorded in 2015 in the Veneto Tumor Registry (North-Est Italian Region), taking both demographic and clinical-pathological variables into consideration.MethodsThe cumulative melanoma-specific survival probabilities were calculated with the Kaplan-Meier method, applying different sociodemographic and clinical-pathological variables. Cox’s proportional hazards model was fitted to the data to assess the association between independent variables and MSS, and also overall survival (OS), calculating the hazard ratios (HR) relative to a reference condition, and adjusting for sex, age, site of tumor, histotype, melanoma ulceration, mitotic count, tumor-infiltrating lymphocytes (TIL), and stage at diagnosis.ResultsCompared with stage I melanoma, the risk of death was increased for stage II (HR 3.31, 95% CI: 0.94-11.76, p=0.064), almost ten times higher for stage III (HR 10.51, 95% CI: 3.16-35.02, p<0.001), and more than a hundred times higher for stage IV (HR 117.17, 95% CI: 25.30-542.62, p<0.001). Among the other variables included in the model, the presence of mitoses and histological subtype emerged as independent risk factors for death.ConclusionsThe multivariable analysis disclosed that older age, tumor site, histotype, mitotic count, and tumor stage were independently associated with a higher risk of death. Data on survival by clinical and morphological characteristics could be useful in modelling, planning, and managing the most appropriate treatment and follow-up for patients with CMM.Alessandra BujaAndrea BardinGiovanni DamianiGiovanni DamianiGiovanni DamianiManuel ZorziChiara De ToniRiccardo FusinatoRomina SpinaAntonella VecchiatoPaolo Del FioreSimone MocellinSimone MocellinVincenzo BaldoMassimo RuggeMassimo RuggeCarlo Riccardo RossiFrontiers Media S.A.articlemelanomaclinical characteristicssurvivalepidemiologycancer survivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
melanoma clinical characteristics survival epidemiology cancer survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
melanoma clinical characteristics survival epidemiology cancer survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Alessandra Buja Andrea Bardin Giovanni Damiani Giovanni Damiani Giovanni Damiani Manuel Zorzi Chiara De Toni Riccardo Fusinato Romina Spina Antonella Vecchiato Paolo Del Fiore Simone Mocellin Simone Mocellin Vincenzo Baldo Massimo Rugge Massimo Rugge Carlo Riccardo Rossi Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
| description |
IntroductionAmong white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. Meanwhile, there has also been a significant improvement in 5-year survival among patients with melanoma. This population-based cohort study investigates the five-year melanoma-specific survival (MSS) for all melanoma cases recorded in 2015 in the Veneto Tumor Registry (North-Est Italian Region), taking both demographic and clinical-pathological variables into consideration.MethodsThe cumulative melanoma-specific survival probabilities were calculated with the Kaplan-Meier method, applying different sociodemographic and clinical-pathological variables. Cox’s proportional hazards model was fitted to the data to assess the association between independent variables and MSS, and also overall survival (OS), calculating the hazard ratios (HR) relative to a reference condition, and adjusting for sex, age, site of tumor, histotype, melanoma ulceration, mitotic count, tumor-infiltrating lymphocytes (TIL), and stage at diagnosis.ResultsCompared with stage I melanoma, the risk of death was increased for stage II (HR 3.31, 95% CI: 0.94-11.76, p=0.064), almost ten times higher for stage III (HR 10.51, 95% CI: 3.16-35.02, p<0.001), and more than a hundred times higher for stage IV (HR 117.17, 95% CI: 25.30-542.62, p<0.001). Among the other variables included in the model, the presence of mitoses and histological subtype emerged as independent risk factors for death.ConclusionsThe multivariable analysis disclosed that older age, tumor site, histotype, mitotic count, and tumor stage were independently associated with a higher risk of death. Data on survival by clinical and morphological characteristics could be useful in modelling, planning, and managing the most appropriate treatment and follow-up for patients with CMM. |
| format |
article |
| author |
Alessandra Buja Andrea Bardin Giovanni Damiani Giovanni Damiani Giovanni Damiani Manuel Zorzi Chiara De Toni Riccardo Fusinato Romina Spina Antonella Vecchiato Paolo Del Fiore Simone Mocellin Simone Mocellin Vincenzo Baldo Massimo Rugge Massimo Rugge Carlo Riccardo Rossi |
| author_facet |
Alessandra Buja Andrea Bardin Giovanni Damiani Giovanni Damiani Giovanni Damiani Manuel Zorzi Chiara De Toni Riccardo Fusinato Romina Spina Antonella Vecchiato Paolo Del Fiore Simone Mocellin Simone Mocellin Vincenzo Baldo Massimo Rugge Massimo Rugge Carlo Riccardo Rossi |
| author_sort |
Alessandra Buja |
| title |
Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
| title_short |
Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
| title_full |
Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
| title_fullStr |
Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
| title_full_unstemmed |
Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
| title_sort |
prognosis for cutaneous melanoma by clinical and pathological profile: a population-based study |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/5f72f641fe674fc49f5331b34d148773 |
| work_keys_str_mv |
AT alessandrabuja prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT andreabardin prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT giovannidamiani prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT giovannidamiani prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT giovannidamiani prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT manuelzorzi prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT chiaradetoni prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT riccardofusinato prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT rominaspina prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT antonellavecchiato prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT paolodelfiore prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT simonemocellin prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT simonemocellin prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT vincenzobaldo prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT massimorugge prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT massimorugge prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT carloriccardorossi prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy |
| _version_ |
1718426726523994112 |